An exploratory analysis of the pivotal phase 3 ADAURA trial (NCT02511106) found that treatment with adjuvant osimertinib (Tagrisso) led to improved disease-free survival (DFS) for patients with EGFR-mutated non-small cell lung cancer (NSCLC), irrespective of prior adjuvant chemotherapy received or disease stage, according to results presented during the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer (WCLC).1
In the overall patient population, adjuvant osimertinib resulted in an 84% reduction in the risk of disease recurrence or death in patients who had previously received adjuvant chemotherapy (HR, 0.16; 95% CI, 0.10-0.26); the reduction was slightly lower, at 77% (HR, 0.23; 95% CI, 0.13-0.40), in those who had not received chemotherapy. Notably, the DFS benefit achieved with adjuvant osimertinib proved to be comparable across all stages of…
